Detalles de la búsqueda
1.
Breast-Conserving Therapy is Associated with Improved Survival Without an Increased Risk of Locoregional Recurrence Compared with Mastectomy in Both Clinically Node-Positive and Node-Negative Breast Cancer Patients.
Ann Surg Oncol
; 30(11): 6413-6424, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37358683
2.
Impact of TAILORx on chemotherapy prescribing and 21-gene recurrence score-guided treatment costs in a population-based cohort of patients with breast cancer.
Cancer
; 128(4): 665-674, 2022 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34855202
3.
Risk of recurrence and pregnancy outcomes in young women with breast cancer who do and do not undergo fertility preservation.
Breast Cancer Res Treat
; 195(2): 201-208, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35908122
4.
Sentinel Node Biopsy Should Not be Routine in Older Patients with ER-Positive HER2-Negative Breast Cancer Who Are Willing and Able to Take Hormone Therapy.
Ann Surg Oncol
; 28(11): 5950-5957, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-33817760
5.
The impact of new systemic therapies on survival and time on hormonal treatment in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: A population-based study in British Columbia from 2003 to 2013.
Cancer
; 126(5): 971-977, 2020 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31750938
6.
Willingness of breast cancer patients to undergo biopsy and breast cancer clinicians' practices around seeking biopsy at the time of breast cancer relapse.
Breast Cancer Res Treat
; 168(1): 221-228, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-29181718
7.
Mammographic non-dense area and breast cancer risk in postmenopausal women: a causal inference approach in a case-control study.
Breast Cancer Res Treat
; 170(1): 159-168, 2018 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-29516373
8.
ASO Visual Abstract: Breast-Conserving Therapy is Associated with Improved Survival without an Increased Risk of Locoregional Recurrence Compared to Mastectomy in Both Clinically Node Positive and Node Negative Breast Cancer Patients.
Ann Surg Oncol
; 30(11): 6425-6426, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37516729
9.
A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer.
Breast Cancer Res
; 19(1): 54, 2017 05 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-28464908
10.
Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed.
Breast Cancer Res Treat
; 161(3): 549-556, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-28000014
11.
Lifetime moderate-to-vigorous physical activity and ER/PR/HER-defined post-menopausal breast cancer risk.
Breast Cancer Res Treat
; 165(1): 201-213, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28589367
12.
Genetic variation in vitamin D-related genes and risk of breast cancer among women of European and East Asian descent.
Tumour Biol
; 37(5): 6379-87, 2016 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-26631034
13.
Breast conserving surgery combined with radiation therapy offers improved survival over mastectomy in early-stage breast cancer.
Am J Surg
; 231: 70-73, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-37246127
14.
Circulating tumour mutation detection in triple-negative breast cancer as an adjunct to tissue response assessment.
NPJ Breast Cancer
; 10(1): 3, 2024 Jan 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38182588
15.
Increased risk of breast cancer associated with long-term shift work in Canada.
Occup Environ Med
; 70(12): 831-8, 2013 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-23817841
16.
Does age affect outcome with breast cancer?
Breast
; 70: 25-31, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37300985
17.
Implementation of pharmacogenetic testing in oncology: DPYD-guided dosing to prevent fluoropyrimidine toxicity in British Columbia.
Front Pharmacol
; 14: 1257745, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37745065
18.
Assessing the real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu positive breast cancer.
Oncologist
; 17(2): 164-71, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22302231
19.
Response to "Do metastasis-free interval less or more than 24 months for recurrent metastatic breast cancer and primary surgery for de novo metastatic breast cancer matter for survival?"
Breast Cancer Res Treat
; 162(2): 397-398, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28110478
20.
Personalizing Adjuvant Endocrine Therapy for Early-Stage Hormone Receptor-Positive Breast Cancer.
Am Soc Clin Oncol Educ Book
; 42: 1-13, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35623026